Characteristics of the antihistamine effect of TAK-427, a novel imidazopyridazine derivative

Inflammation Research

Volumn 52, Issue 5, 2003, Pages 206-214

  Fukuda, S ^a   Midoro, K ^a   Yamasaki, M ^a   Gyoten, M ^a   Kawano, Y ^a   Fukui, H ^b   Ashida, Y ^a   Nagaya, H ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Antihistamine activity; Sedation; TAK 427

Indexed keywords

2 [6 [[3 [4 (DIPHENYLMETHOXY)PIPERIDINO]PROPYL]AMINO]IMIDAZO[1,2 B]PYRIDAZIN 2 YL] 2 METHYLPROPIONIC ACID; ANTIHISTAMINIC AGENT; AZELASTINE; CETIRIZINE; EPINASTINE; HISTAMINE H1 RECEPTOR; KETOTIFEN; MEPYRAMINE; OXATOMIDE; PENTOBARBITAL; TAK 427; TERFENADINE; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GUINEA PIG; IC 50; MALE; MOUSE STRAIN; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; SEDATION; SKIN MANIFESTATION; SLEEP TIME;

EID: 0037837024     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110300073     Document Type: Article

References (16)

1. 1 receptor antagonist drugs. N Engl J Med 1994; 330: 1663-70.
2. 1 antihistamine chlorpheniramine maleate on histamine induced symptoms in the human conjunctiva. Allergy 1982; 37: 203-8.
3. 1 antagonist, in seasonal allergic rhinoconjunctivitis. Allergy 1987; 42: 512-5.
4. Nicholson AN. Antihistamines and sedation. Lancet 1983; ii: 211-2.
5. Nicholson AN. New antihistamines free of sedative side-effects. Trends Pharmacol Sci 1987; 8: 247-9.
6. 1 receptor antagonism: Studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991; 104: 270-6.
7. 3H] pyrilamine may predict sedative properties of psychoactive drugs. Eur J Pharmacol 1979; 60: 391-2.
8. 2 antagonist. Neuropharmacology 1985; 24: 245-50.
9. Monti JE. Involvement of histamine in the control of the waking state. Life Sci. 1993; 53: 1331-8.
10. 1-receptor activation reduce a background leakage potassium current. Neuroscience 1994; 59: 579-88.
11. Fukuda S, Midoro K, Kamei T, Gyoten M, Kawano Y, Ashida Y et al. Inhibition of allergic dermal inflammation by the novel imidazopyridazine derivative TAK-427 in a guinea pig experimental model of eczema. J Pharmacol Exp Ther 2002; 303: 1283-90.
12. Fukui H, Fujimoto K, Mizuguti H, Sakamoto K, Horio Y, Takai S et al. Molecular cloning of the human histamine H, receptor gene. Biochem Biopphys Res Commun 1994; 15: 894-901.
13. Woodward DF, Nieves AL, Spada CS, Williams LS and Tuckett RE. Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen. J Pharmacol Exp Ther 1995; 272: 758-65.
14. Gyoten M, Nagaya H, Fukuda S, Ashida Y and Kawano Y. Synthesis of eosinophil infiltration inhibitors with antihistaminic activity. Chem Pharm Bull 2003; 51: 122-133.
15. Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Sawai Y et al. Histamine H, receptor occupancy in human brains after single oral doses of histamine H, antagonists measured by positron emission tomography. Br J Pharmacol 1995; 116: 1649-55.
16. Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Asakura Met al. Positron emission tomographic study of central histamine HLreceptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Meth Find Exp Clin Pharmacol 1995; 17(C): 64-9.